The US FDA has granted accelerated approval to doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq), a plasma DNA-Based immunotherapy, to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis (RRP). Mechanism of Action Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd are designed to express human papillomavirus (HPV) types 6 and 11 antigens and interleukin-12 (IL-12), stimulating an immune response against HPV-infected cells.

Clinical Evidence The efficacy of doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd was evaluated in an open-label, single-arm clinical study involving 26 adults with RRP who required at least three surgical papilloma excisions during the 12 months before treatment. Seven patients (27%) achieved a complete response, defined as requiring no surgical papilloma excision during…